Ciprofloxacin inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes

British Journal of Pharmacology

Volumn 161, Issue 1, 2010, Pages 229-240

  Mori, S ^a   Takahashi, H K ^b   Liu, K ^b   Wake, H ^b   Zhang, J ^b   Liu, R ^b   Yoshino, T ^b   Nishibori, M ^a  

^a SHUJITSU UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

adhesion molecule; advanced glycation end products; ciprofloxacin; cyclic adenosine monophosphate; cyclooxygenase 2; human; monocytes; peripheral blood mononuclear cells; prostaglandins E2; protein kinase A

Indexed keywords

ADVANCED GLYCATION END PRODUCT; B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CIPROFLOXACIN; CYCLIC AMP; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; CELL ADHESION MOLECULES; CELL PROLIFERATION; CIPROFLOXACIN; CYCLIC AMP; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYMPHOCYTES; MONOCYTES;

EID: 77955836606     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00880.x     Document Type: Article

References (37)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Bastien L, Sawyer N, Grygorczyk R, Metters KM, Adam M (1994). Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem 269 : 11873 11877.
3. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP (1998). AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37 : 586 600.
4. Brownlee M (1995). Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46 : 223 234.
5. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ et al. (2004). Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24 : 1266 1271.
6. Camacho SA, Heath WR, Carbone FR, Sarvetnick N, LeBon A, Karlsson L et al. (2001). A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nat Immunol 6 : 523 529.
7. Coleman RA, Smith WL, Narumiya S (1994). VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptor and their subtypes. Pharmacol Rev 46 : 205 229.
8. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R et al. (2006). Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 : 2716 2723.
9. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ (1994). The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 9 : 406 411.
10. Enomoto M, Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A et al. (2006). Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 55 : 912 917. (Pubitemid 43902894)
11. Fitzsimmons C, Proudfoot D, Bowyer DE (1999). Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. Atherosclerosis 142 : 287 293.
12. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M et al. (2004). AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66 : 2137 2147.
13. Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A et al. (2005). Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 25 : 2157 2163.
14. Issa MM, Nejem RM, El-Abadla NS, El-Naby MK, Roshdy AA, Kheiralla ZA (2007). Effects of paracetamol on the pharmacokinetics of ciprofloxacin in plasma using a microbiological assay. Clin Drug Investig 27 : 463 467.
15. Jain SK, Kannan K, Lim G, McVie R, Bocchini JA Jr. (2002). Hyperketonemia increases tumor necrosis factor-alpha secretion in cultured U937 monocytes and Type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency. Diabetes 51 : 2287 2293.
16. Liao H, Zakhaleva J, Chen W (2009). Cells and tissue interactions with glycated collagen and their relevance to delayed diabetic wound healing. Biomaterials 30 : 1689 1696.
17. Licitra CM, Brooks RG, Sieger BE (1987). Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection. Antimicrob Agents Chemother 31 : 805 807.
18. Lorenowicz MJ, Fernandez-Borja M, Hordijk PL (2007). cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 27 : 1014 1022.
19. Mamputu JC, Renier G (2004). Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 75 : 1062 1069.
20. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T (2007). Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 7 : 188 190.
21. Ngo BT, Hayes KD, DiMiao DJ, Srinivasan SK, Huerter CJ, Rendell MS (2005). Manifestations of cutaneous diabetic microangiopathy. Am J Clin Dermatol 6 : 225 237.
22. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr., Chow WS et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 : 1025 1031.
23. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN (1989). Therapy of lower extremity infections with ciprofloxacinin patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 86 : 801 808.
24. Ranger AM, Das MP, Kuchroo VK, Glimcher LH (1996). B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int Immunol 10 : 1549 1560.
25. Riesbeck K (2002). Immunomodulating activity of quinolones: review. J Chemother 14 : 3 12.
26. Riesbeck K, Forsgren A (1990). Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. Eur J Clin Microbiol Infect Dis 9 : 409 413.
27. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD et al. (1994). Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A 91 : 8807 8811.
28. Takahashi HK, Iwagaki H, Tamura R, Xue D, Sano M, Mori S et al. (2003). Unique regulation profile of prostaglandin E1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 307 : 1188 1195.
29. Takahashi HK, Iwagaki H, Xue D, Katsuno G, Sugita S, Mizuno K et al. (2005). Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18- treated monocytes. Antimicrob Agents Chemother 49 : 3228 3233.
30. Takahashi HK, Mori S, Wake H, Yoshino T, Ohashi K, Tanaka N et al. (2009a). Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 330 : 89 98.
31. 2 inhibits advanced glycation end products-induced adhesion molecule expression, cytokine production and lymphocyte proliferation in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 331 : 656 670.
32. Takedo A, Yasuda T, Miyata T, Mizuno K, Li M, Yoneyama S et al. (1996). Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 221 : 17 20.
33. Takeuchi M, Yamagishi S (2004). TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 63 : 449 452.
34. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y (2000). Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 6 : 114 125.
35. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR (2008). Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 23 : 422 430.
36. Wake H, Takahashi HK, Mori S, Liu K, Yoshino T, Nishibori M (2009). Histamine inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes. J Pharmacol Exp Ther 330 : 826 833.
37. Yamagishi S, Imaizumi T (2005). Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 : 2279 2299.